Dr. Edward M. Wolin, MD

Dr. Wolin practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Wolin's NPI, 1780658070, was assigned on February 14, 2006. Dr. Wolin graduated from Yale School of Medicine in 1974. Dr. Wolin holds New York license 280009.

Dr. Wolin's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Wolin also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Wolin's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is Montefiore Einstein Faculty Practice Group. Dmand AI also links Dr. Wolin to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wolin practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Wolin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Wolin is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Wolin's licenses on file in 6 states: New York, Oregon, California, New Jersey, Kentucky and Iowa.

Dmand AI lists breast cancer and prostate cancer among the conditions Dr. Wolin treats.

CMS data shows 513 Medicare services from Dr. Wolin across 5 procedure codes in 2024, for 178 Medicare patients. Medicare paid $47,472 for them.

CMS counts 178 Medicare patients who saw Dr. Wolin in 2024. The largest group is 65 to 74, with 99 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wolin's median patient age at 63, with 56% women.

In 2024, Dr. Wolin wrote 153 Medicare Part D claims for 30 patients. CMS names the drug for 103 of them, across 3 drugs with 11 or more claims each, at $639,424 in total drug cost. In 2023, CMS named 181 claims across 6 drugs.

Dr. Wolin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wolin as offering telehealth.

Dmand AI links 72 papers to Dr. Wolin, published from 2010 to 2025. 2017 was the busiest year, with 11. The most frequent topics are Neuroendocrine Tumors, Antineoplastic Agents and Pancreatic Neoplasms. Dr. Wolin has published most often in Pancreas. Dr. Wolin's most frequent co-authors are Jonathan R. Strosberg, MD, James C. Yao, MD and Run Yu, MD.

Dmand AI links Dr. Wolin to 10 clinical trials, 6 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Neuroendocrine Tumors, Carcinoid Tumor and Neuroectodermal Tumors. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 95 general payments to Dr. Wolin from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 50% of the total. Lexicon Pharmaceuticals, Inc. paid the most, $15,785. It also lists 5 research payments totaling $29,220 from 2016 to 2018.

Dmand AI lists 5 awards for Dr. Wolin, most recently Patient’s Choice Physician Award in 2012.

Dr. Wolin graduated from Yale School of Medicine in 1974.

Dr. Wolin is in network with 17 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.